Tumour Response in Uveal Melanomas Treated with Proton Beam Therapy

Post-proton therapy surveillance of uveal melanomas relies on decreased thickness on repeat ultrasound B every 6 months for 2 years and yearly thereafter. Earlier pseudoprogression, a phenomenon described in other tumour types within the first months of irradiation, can also be observed in uveal melanomas and may lead to inappropriate enucleation. The Collaborative Ocular Melanoma Study (COMS) has defined ultrasound criteria to identify tumour progression after brachytherapy. We aimed to determine the reliability of ultrasound as a means to measure tumour height after proton therapy and predict local relapse.

Source: Clinical Oncology - September 15, 2015 Category: Radiology Authors: C. Maschi, J. Thariat, J. Herault, J.-P. Caujolle Tags: Original Article Source Type: research